RR22 Antibody

What is RRM2 and why is it important in cell biology?

RRM2 (Ribonucleotide Reductase M2) is a critical subunit of the ribonucleotide reductase enzyme complex that catalyzes the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis and repair. This process is fundamental to maintaining balanced dNTP pools required for DNA replication and genomic stability . The activity and expression of RRM2 are tightly regulated throughout the cell cycle, with highest expression typically occurring during S phase. RRM2 dysregulation has been implicated in various pathological conditions, including cancer progression and chemotherapy resistance, making it an important target for both basic research and therapeutic development. Its phosphorylation, particularly at the Thr33 residue, serves as a key regulatory mechanism that controls protein stability and function.

What are the most common applications for Phospho-RRM2 (Thr33) antibodies in research?

Phospho-RRM2 (Thr33) antibodies are valuable tools in multiple research applications, with Western blotting and immunoprecipitation being the most widely utilized techniques . In Western blotting (recommended dilution 1:1000), these antibodies enable researchers to detect and quantify the phosphorylation status of RRM2 at Thr33 in various experimental conditions, including cell cycle progression studies, drug response analyses, and disease models. For immunoprecipitation (recommended dilution 1:50), these antibodies facilitate the isolation of phosphorylated RRM2 complexes, allowing for subsequent analysis of protein-protein interactions and post-translational modifications. These applications provide critical insights into the regulation of nucleotide metabolism, DNA replication, and cell cycle control in both normal physiology and pathological states such as cancer.

What are the optimal conditions for detecting phosphorylated RRM2 in Western blotting?

For optimal detection of phosphorylated RRM2 in Western blotting experiments, researchers should implement several critical considerations. First, use freshly prepared lysates with phosphatase inhibitors to preserve the phosphorylation state. The Phospho-RRM2 (Thr33) antibody performs optimally at a 1:1000 dilution , but this may require optimization based on your specific sample type and protein abundance. The expected molecular weight for RRM2 is approximately 45 kDa , so appropriate molecular weight markers should be included. For optimal results, use 4-20% gradient gels with extended separation time in the 40-50 kDa range. After transfer to membrane (preferably PVDF), blocking with 5% BSA rather than milk is recommended as milk contains phosphatases that may reduce signal. Overnight primary antibody incubation at 4°C followed by high-sensitivity detection systems tends to yield the best results for detecting endogenous phosphorylation levels. Always include positive controls (S-phase synchronized cells) and negative controls (phosphatase-treated lysates) to validate specificity.

How should researchers approach immunoprecipitation experiments with Phospho-RRM2 antibodies?

When conducting immunoprecipitation experiments with Phospho-RRM2 antibodies, researchers should follow a methodical approach to ensure specific and efficient pulldown of the target protein. Begin with freshly prepared cell lysates containing 500-1000 μg of total protein and maintain phosphatase inhibitors throughout the procedure. Pre-clear lysates with protein A/G beads to reduce non-specific binding . For immunoprecipitation, the recommended antibody dilution is 1:50 , which typically corresponds to 2-4 μg of antibody per reaction. Incubate the antibody-lysate mixture overnight at 4°C with gentle rotation to maximize binding while preserving antibody integrity. After capturing antibody-protein complexes with protein A/G beads, perform stringent washing steps (at least 5 washes) with detergent-containing buffers to remove non-specific interactions. For elution, use either gentle (non-denaturing) conditions if preserving protein activity is required, or denaturing conditions (SDS sample buffer) for subsequent SDS-PAGE analysis. Always run parallel control immunoprecipitations with non-specific IgG to distinguish between specific and background signals.

What cell models are most appropriate for studying RRM2 phosphorylation dynamics?

The selection of appropriate cell models is crucial for studying RRM2 phosphorylation dynamics effectively. Based on the antibody's demonstrated reactivity with human, mouse, and rat samples , researchers have flexibility in choosing physiologically relevant models. Rapidly dividing cell lines such as HeLa, U2OS, or NIH/3T3 provide excellent systems for studying cell cycle-dependent regulation of RRM2 phosphorylation due to their robust S-phase entry and well-characterized cell cycle profiles. Cancer cell lines with altered RRM2 expression or regulation (particularly those derived from tissues with high proliferative indices) offer valuable insights into pathological contexts. For more physiologically relevant studies, primary cells isolated from tissues with high replication rates (such as bone marrow, intestinal crypts, or developing embryonic tissues) can reveal tissue-specific regulation mechanisms. Cell synchronization protocols (double thymidine block, nocodazole treatment, or serum starvation/release) are highly recommended to enrich for specific cell cycle phases, allowing precise temporal mapping of RRM2 phosphorylation events. When comparing different cell types, it's essential to normalize phospho-RRM2 levels to total RRM2 protein to accurately assess phosphorylation status independent of expression level variations.

How can Phospho-RRM2 (Thr33) antibodies be utilized in cancer research?

Phospho-RRM2 (Thr33) antibodies serve as powerful tools in cancer research by enabling the investigation of dysregulated cell cycle control and nucleotide metabolism that characterize many malignancies. Researchers can employ these antibodies to evaluate the phosphorylation status of RRM2 across tumor tissues and cell lines, correlating phosphorylation patterns with proliferation rates, invasiveness, and treatment resistance . Given that CDK-mediated phosphorylation targets RRM2 for degradation to maintain balanced dNTP pools , aberrant phosphorylation may indicate disrupted cell cycle checkpoints or nucleotide metabolism in cancer cells. These antibodies can be particularly valuable in studying the effects of CDK inhibitors, which are emerging as important cancer therapeutics. By monitoring RRM2 phosphorylation before and after treatment, researchers can assess whether these drugs effectively disrupt nucleotide metabolism as part of their anti-cancer mechanism. Additionally, combinatorial studies examining RRM2 phosphorylation alongside other cell cycle markers can provide comprehensive insights into how cancer cells evade normal proliferative controls through alterations in nucleotide synthesis pathways.

What is the relationship between RRM2 phosphorylation and DNA damage response pathways?

The relationship between RRM2 phosphorylation and DNA damage response (DDR) pathways represents a critical intersection of nucleotide metabolism and genome integrity maintenance. When DNA damage occurs, cells must carefully regulate dNTP pools to support repair processes without introducing additional errors. The CDK-mediated phosphorylation of RRM2 at Thr33, which targets the protein for degradation , provides a mechanism to rapidly adjust dNTP availability in response to genotoxic stress. Following DNA damage, cells typically arrest at cell cycle checkpoints, during which CDK activity is suppressed. This suppression can lead to reduced RRM2 phosphorylation at Thr33, potentially stabilizing the protein and supporting increased dNTP production for DNA repair. Conversely, during recovery from DNA damage, resumption of CDK activity and subsequent RRM2 phosphorylation helps restore normal dNTP levels. Research using phospho-specific RRM2 antibodies can reveal how different DNA-damaging agents affect this regulatory mechanism and how cancer cells may exploit alterations in RRM2 phosphorylation to survive genotoxic therapies. Understanding this relationship has significant implications for improving the efficacy of both conventional chemotherapeutics and targeted therapies that induce DNA damage.

How do cell cycle inhibitors affect the phosphorylation status of RRM2?

Cell cycle inhibitors, particularly those targeting cyclin-dependent kinases (CDKs), have profound effects on the phosphorylation status of RRM2. Since CDK-mediated phosphorylation of RRM2 at Thr33 is a key mechanism targeting the protein for degradation , CDK inhibitors can directly interfere with this regulatory process. When CDK activity is blocked by inhibitors such as palbociclib (CDK4/6 inhibitor), ribociclib, or pan-CDK inhibitors like flavopiridol, researchers typically observe decreased phosphorylation at the Thr33 site. This reduced phosphorylation leads to RRM2 stabilization and potential accumulation, which can significantly alter cellular dNTP pools. Interestingly, the effects may vary depending on the specific CDK inhibitor used, as different CDKs may contribute differentially to RRM2 phosphorylation throughout the cell cycle. Using phospho-RRM2 (Thr33) antibodies, researchers can precisely monitor these changes through Western blotting and immunoprecipitation , providing valuable insights into the mechanism of action of these therapeutically important compounds. This application is particularly relevant for understanding how cancer cells might develop resistance to CDK inhibitors through adaptations in nucleotide metabolism pathways.

How can researchers address non-specific binding issues with Phospho-RRM2 (Thr33) antibodies?

Non-specific binding is a common challenge when working with phospho-specific antibodies like the Phospho-RRM2 (Thr33) antibody. To address this issue, researchers should implement a systematic troubleshooting approach. First, optimize blocking conditions by testing different blocking agents (BSA, casein, commercial blocking buffers) and concentrations to minimize background without compromising specific signal. When performing Western blotting, increasing the stringency of wash steps by adding higher concentrations of detergent (0.1-0.3% Tween-20) and extending wash times can significantly reduce non-specific binding . For more persistent issues, consider adding a phosphopeptide competition assay where the antibody is pre-incubated with a phosphopeptide matching the Thr33 epitope before application to the sample; this should eliminate specific signal while leaving non-specific binding intact, helping to distinguish between true and false signals. Additionally, include proper controls in every experiment: phosphatase-treated samples should show reduced or absent signal, while samples from conditions known to enhance RRM2 phosphorylation (such as S-phase synchronized cells) should show increased signal. Finally, if non-specific binding persists across multiple experimental conditions, consider using alternative detection methods such as proximity ligation assays or phospho-flow cytometry, which may offer improved specificity for detecting phosphorylated RRM2.

How should researchers interpret contradictory results between phosphorylation status and protein function?

Interpreting contradictory results between RRM2 phosphorylation status and protein function requires a nuanced approach that considers the complexity of post-translational regulation. First, verify whether the contradictions are methodological artifacts by repeating experiments with alternative techniques; for instance, if Western blotting shows increased phosphorylation but functional assays indicate higher activity , confirm phosphorylation status using immunoprecipitation or mass spectrometry. Consider that Thr33 is just one of several phosphorylation sites on RRM2, and other sites may have compensatory or dominant effects on protein function that override Thr33 phosphorylation impacts. The timing of measurements is crucial – phosphorylation states change rapidly, so apparent contradictions might reflect different snapshots of a dynamic process rather than true discrepancies. Cell-type specific factors can also influence the relationship between phosphorylation and function, including variations in phosphatase activity, subcellular localization mechanisms, or the presence of binding partners that might sequester phosphorylated RRM2 or alter its degradation rate despite phosphorylation. Additionally, investigate whether other post-translational modifications (ubiquitination, acetylation, or additional phosphorylation sites) might be interfering with the expected relationship between Thr33 phosphorylation and protein degradation . Finally, consider the theoretical possibility that under certain cellular stresses or pathological conditions, the normal relationship between phosphorylation and function might be fundamentally altered through mechanisms not yet fully understood in the literature.

What emerging technologies might enhance the study of RRM2 phosphorylation dynamics?

Several cutting-edge technologies are poised to revolutionize our understanding of RRM2 phosphorylation dynamics. Live-cell phosphorylation sensors based on FRET (Förster Resonance Energy Transfer) technology could enable real-time visualization of RRM2 phosphorylation events in living cells, providing unprecedented temporal resolution. CRISPR-Cas9 gene editing approaches to create endogenously tagged RRM2 variants (phosphomimetic or phospho-deficient) would allow precise dissection of phosphorylation site functions without overexpression artifacts. Single-cell phosphoproteomics is rapidly advancing and could reveal cell-to-cell heterogeneity in RRM2 phosphorylation status that bulk analyses miss . Proximity-dependent labeling methods like BioID or TurboID fused to RRM2 could identify the protein interaction network that changes upon phosphorylation at Thr33. Advanced microscopy techniques such as super-resolution microscopy combined with phospho-specific antibodies may reveal previously unknown spatial organization of phosphorylated RRM2 within subcellular compartments. Additionally, the integration of machine learning approaches with large-scale phosphoproteomic datasets could identify novel patterns in RRM2 regulation across different cell states and disease conditions. These technological advances will likely provide deeper insights into how CDK-mediated phosphorylation of RRM2 orchestrates nucleotide metabolism throughout the cell cycle and in response to various cellular stresses .

How might studies of RRM2 phosphorylation contribute to cancer therapy development?

Research into RRM2 phosphorylation mechanisms holds significant promise for advancing cancer therapy development through multiple avenues. Since CDK-mediated phosphorylation targets RRM2 for degradation to maintain balanced dNTP pools , understanding these regulatory pathways could reveal novel vulnerabilities in cancer cells that depend on elevated nucleotide metabolism. Therapeutic approaches might exploit the differential phosphorylation patterns of RRM2 in normal versus cancer cells to selectively target malignant cells while sparing normal tissues. The development of small molecules that specifically modulate RRM2 phosphorylation or mimic the binding of phosphorylated RRM2 to its degradation machinery could provide a new class of targeted therapeutics. Additionally, phospho-RRM2 status could serve as a biomarker for predicting response to existing therapies, particularly CDK inhibitors and conventional chemotherapeutics that interfere with DNA synthesis. Combination therapies that simultaneously target RRM2 function and its phosphorylation-dependent regulation might overcome resistance mechanisms observed with single-agent approaches. The development of proteolysis-targeting chimeras (PROTACs) directed against phosphorylated RRM2 represents another promising direction, potentially enabling selective degradation of this form of the protein in cancer cells. As our understanding of RRM2 phosphorylation dynamics grows through research utilizing phospho-specific antibodies , these insights will continue to inform increasingly sophisticated therapeutic strategies targeting nucleotide metabolism in cancer.

What interdisciplinary approaches could advance our understanding of RRM2 regulation?

Interdisciplinary approaches hold enormous potential for deepening our understanding of RRM2 regulation beyond traditional biochemical perspectives. Integrating computational biology with experimental data could yield predictive models of how RRM2 phosphorylation at Thr33 and other sites responds to various cellular signals, providing testable hypotheses about regulatory networks . Systems biology approaches examining the interplay between RRM2 phosphorylation, metabolic flux through nucleotide synthesis pathways, and cell cycle progression could reveal emergent properties not obvious from studying these processes in isolation. Structural biology techniques like cryo-electron microscopy of RRM2 in different phosphorylation states might illuminate how phosphorylation alters protein conformation and interactions with degradation machinery. Chemical biology approaches, including the development of covalent probes for specific RRM2 phosphorylation states, could enable selective targeting of different RRM2 populations within cells. Evolutionary biology perspectives comparing RRM2 phosphorylation sites across species could identify conserved regulatory mechanisms, suggesting fundamental importance in cellular function. Additionally, collaborations with clinical researchers could bridge laboratory findings on RRM2 phosphorylation with patient data, potentially identifying correlations between phosphorylation patterns and disease outcomes or treatment responses. These diverse interdisciplinary approaches would provide complementary insights into the complex regulation of RRM2, potentially uncovering novel therapeutic opportunities and fundamental principles of nucleotide metabolism control.